SMARCA2
MOLECULAR TARGETSWI/SNF related BAF chromatin remodeling complex subunit ATPase 2
SMARCA2 (SWI/SNF related BAF chromatin remodeling complex subunit ATPase 2) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SMARCA2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | molibresib | 3.81 | 44 |
| 2 | gsk046 | 2.40 | 10 |
| 3 | gsk620 | 2.30 | 9 |
| 4 | gsk778 | 2.08 | 7 |
| 5 | Genistein | 1.10 | 2 |
| 6 | alsterpaullone | 1.10 | 2 |
| 7 | calycosin | 1.10 | 2 |
| 8 | kenpaullone | 1.10 | 2 |
| 9 | chrysin | 0.69 | 1 |
| 10 | Disulfiram | 0.69 | 1 |
| 11 | Lovastatin | 0.69 | 1 |
About SMARCA2 as a Drug Target
SMARCA2 (SWI/SNF related BAF chromatin remodeling complex subunit ATPase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented SMARCA2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SMARCA2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.